StockData
Fennec Pharmaceuticals Inc. logo

Fennec Pharmaceuticals Inc. (FENC) stock

FENCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/3088% above fair value
$13.58+0.82 (+6.43%)

Close on Nov 17, 2026Market cap $476.21MP/E –Yield –

Fennec Pharmaceuticals price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Fennec Pharmaceuticals's price to book ratio was 8.8× on Nov 11, 2026, against 61.0× a year earlier. Over the last 5 years it ranged from 3.8× to 93.7×, with a median of 8.8×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20268.8×−49.4
2024Jul 31, 202458.2×−35.5
2023Jan 31, 202393.7×+3.8
2022Dec 30, 202289.9×+83.9
2021Dec 31, 20216.0×−0.1
2020Dec 31, 20206.2×−2.4
2019Dec 31, 20198.6×+3.8
2018Dec 31, 20184.8×−13.1
2017Dec 29, 201717.9×+17.9
2016Dec 30, 20160.0×–

More Fennec Pharmaceuticals figures

See a number that looks wrong?